News
HER-096, a potential new Parkinson's treatment, has shown promising phase 1 trial results, proving it’s safe, well-tolerated, and effective in reaching the brain in people with Parkinson's. This is a crucial step towards a drug that could slow, stop, or even repair Parkinson's damage.
As the leading funder of Parkinson’s research in Europe, we’re pleased to announce that we’re supporting new projects that hope to bring us closer to better treatments to transform the lives of those affected by Parkinson’s.
Here are the latest medication supply issues we are aware of.
Today, as the UK government launches its consultation to inform its new 10 year plan for the NHS workforce for England. We've outlined the vital changes needed to make sure people with Parkinson’s can access the care they need.
This month we’re relaunching our Can’t Wait campaign to end the long waits for care across England and Scotland. And we need your help.
We’ve awarded Cellestial Health £55,000 to continue exploring networks of brain cells that may hold answers for new treatments for Parkinson’s.
Thanks to our crucial funding, a new drug treatment, created by NRG Therapeutics, is moving forwards.
Parkinson's UK is supporting a new national accreditation for exercise professionals.
We’re calling on the Scottish government to protect social security and invest in mental health services.
Local campaigners across England have been busy speaking to MPs and councillors, and holding events to raise awareness of Parkinson’s and help improve services and support.